What Is IGC Pharma, Inc. (IGC) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, IGC Pharma, Inc.'s intrinsic value is estimated at $0.13, suggesting the stock is overvalued at its current price of $0.27. With 9 out of 11 models flagging downside (-51.2% average return), the market may be pricing in unsustainable growth. Notably, EROIC sees the most upside at +11.3% (fair value: $0.30), while Regime Cross is the most conservative at -96.2% ($0.01). The spread between these extremes — +107.5% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About IGC?
11 of 13 models are currently active for IGC. Of these, 2 models suggest upside while 9 models suggest overvaluation. The Bayesian DCF estimates IGC's intrinsic value at $0.02, implying -91.4% downside from the current price. See which stocks rank higher →
How Does IGC Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, IGC ranks #211 by Quality of Company score. CirclFi's QOC score of 5.0/10 evaluates 32 fundamental signals. A score of 5.0 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
As a healthcare company, IGC Pharma, Inc. operates in a sector where R&D productivity ratio is a critical driver of valuation. Investors evaluating IGC should weigh these sector-specific dynamics alongside our model-derived fair values.
Is IGC a Value Trap?
CirclFi's Value Trap algorithm assigns IGC a score of 38/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
11 of 13 models are active for IGC Pharma, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, IGC Pharma, Inc. is rated at 5.0/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.
The gap between the most bullish and bearish model spans +107.5% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every IGC valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across IGC's 11 active models, average confidence is 25%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad